A multi-centre, double-blinded, randomised controlled trial to determine the efficacy and safety of MV140 in patients with recurrent UTIs in Australia
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Enterococcus-faecalis-FK23/escherichia-coli-vaccine/klebsiella-vaccine/proteus-vulgaris-inactivated-vaccine (Primary)
- Indications Urinary tract infections
- Focus Therapeutic Use
Most Recent Events
- 14 Dec 2023 New trial record
- 07 Dec 2023 According to Trial design published in the BJU International, study candidates will be identified and recruited from inpatients and outpatient clinics across Sydney via referral to the investigation team.
- 07 Dec 2023 Trial design published in the BJU International